Skip to main content
MSLE logo

MSLE

Satellos Bioscience Inc.
$9.79 +0.35 (+3.71%) At close · Jul 10
Market Cap
$206.65M
Shares
20,831,190

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$9.79 Open$9.34 Day$9.34–10.00 52W$4.64–13.40 Avg vol 30d65K Short int83K · 0.4% float · 1.7d Short vol89% DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15 · calm Equity put/call 0.55
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +31%
above
Price vs 50-day avg +39%
above
RSI (14) 76
overbought
MACD trend Positive
52-week position 59%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +67%
trailing
6-month return +27%
trailing
YTD return +67%
this year
Relative strength +18%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.40% of float · ▲ +18.9% MoM · 1.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — 13F breadth
Squeeze score 81
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 83%
annualized · 1-yr
Max drawdown −57%
past year
ATR 7.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+31% Bullish
Price vs 50-day avg
+39% Bullish
RSI (14)
76 Bearish
MACD trend
Positive Bullish
52-week position
59% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.40% of float · ▲ +18.9% MoM · 1.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $5 Now $10 · 59% 52-wk high $13
vs 200-day avg +31% vs 50-day avg +39%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MSLE
Satellos Bioscience Inc.
this stock
$206.65M +66.5% 0.4%
ONC
BeOne Medicines Ltd.
$431.70B -1.7% +22179.2% 878.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$123.19B +9.5% +46.2% 28.8 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$69.63B -13.8% +20.8% 16.2 3.3%
ARGX
Argenx SE
$54.85B +4.4% 2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
31
% held
36.5%
Net QoQ
+7.6M sh
Top holder
Qiming U.S. Healthcare Fu…
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Rising
Shares short
83.5K
Days to cover
1.7d
Change
+13.3K sh
View
Short Volume
Short vol %
89%
As of
Jul 10, 2026
Short Total
View
Fails to Deliver
FTD shares
2.2K
Value
$15.2K
As of
Jun 3, 2026
View
Off-Exchange
Off-exchange %
43.8%
Week of
May 4, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Jul 8, 2026
This year
22
View
Exempt Offerings
Offering
$25.0M
Filed
Jan 3, 2025
View
Earnings & Events
Earnings Calls
Last call
Jun 25, 2026
View
Investor Relations
Latest news
Satellos Reports Six-Month Interi…
Published
Jul 8, 2026
View

Performance

5D 20D 120D MTD YTD
MSLE +31.9% +66.5% +27.5% +25.9% +66.5%
SPY +1.4% +4.1% +9.1% +1.1% +10.7%
vs SPY +30.6% +62.4% +18.4% +24.8% +55.8%
Key facts CIK 1421642 CUSIP 80401L803 Visit website Investor relations